Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Formulary Guide Looks Beyond USP For Principles On Rx Classes

Executive Summary

Medicare's prescription drug plan formulary review guidelines incorporate existing principles set up by outside groups rather than creating new standards

You may also be interested in...



Blues Association Planning Part D Offering For Federal Workers In 2007

The BlueCross BlueShield Association expects to sponsor a Medicare Part D plan within the Federal Employees Health Benefits Program in 2007

Blues Association Planning Part D Offering For Federal Workers In 2007

The BlueCross BlueShield Association expects to sponsor a Medicare Part D plan within the Federal Employees Health Benefits Program in 2007

Medicare Formularies Should Contain “Majority” Of Drugs In Six Classes

Medicare drug plan formularies will be expected to cover the "majority" of products in six specific drug classes, the Centers for Medicare & Medicaid Services final formulary review guidelines state

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel